White Guide and Orange Guide Formatting Project - Pfizer

Orange Guide – Chapter 7: P&T Committee Interactions
Chapter 7: P&T COMMITTEE INTERACTIONS
P&T Committees
Many healthcare organizations, such as hospitals, state Medicaid agencies, and managed care
organizations, maintain lists of preferred drugs that can be prescribed by healthcare professionals
(HCPs) within the organization or that are eligible for reimbursement by the organization. These lists
are commonly called formularies. The Pharmacy and Therapeutics (P&T) Committee of an
organization decides which pharmaceutical products are included on the formulary.
Pharmacy & Therapeutics (P&T) Committee: the committee within an institution or managed care
organization that decides which pharmaceutical products are included on the formulary.
P&T Committees typically make formulary decisions based upon assessments of safety, efficacy,
tolerability and, increasingly, cost-effectiveness. In some cases, organizations with P&T Committees
may be acting on behalf of Medicaid, Medicare Part D or other government healthcare programs. P&T
Committee members are charged with an important responsibility and therefore are expected to avoid
both actual and perceived conflicts of interest when making formulary decisions. It is Pfizer policy not
to engage in any activity that could be construed as improperly influencing the independent judgment
of a P&T Committee member. In fact, consistent with the Pharmaceutical Research and Manufacturers
of America (PhRMA) Code on Interactions with Healthcare Professionals (“PhRMA Code”), any HCPs
hired by Pfizer as speakers or consultants who also serve as members of a P&T Committee must
disclose to the Committee the existence and nature of his or her relationship with Pfizer. This
requirement should generally extend for at least two years beyond the termination of any speaker or
consulting arrangement.
Non-compliance with these policies puts the Company at risk and can subject colleagues to
disciplinary action up to and including termination.
124
Rev. 09/12
Page 2 of 11